Dow Jones Venture Wire
With Drugs In Doubt, Some Biotechs Are Selling Out
- By Brian Gormely
"...Numoda now plans to develop Vitreosolve in the primary indication of vitreomacular adhesion and the secondary indication of inducing a posterior-vitreous detachment in the treatment of diabetic retinopathy. The firm plans new, placebo-controlled studies and is consulting drug-makers to find other ways to groom Vitreosolve for a sale. It aims to speed the auctioning process through technology from an affiliate, Numoda Technologies Inc., that enables potential bidders to see trial data as they are generated."
